Endovascular Systems Market Targets US$214.7 Million Valuation by 2033

Robotic Assisted Endovascular Systems (RAES) refer to advanced medical technology that combines robotics and endovascular procedures.

The global robotic assisted endovascular systems market is anticipated to grow rapidly, with a projected market value of US$ 94.0 million in 2023 and an anticipated CAGR of 8.6% over the forecast period. By 2033, the market is estimated to be valued US$ 214.7 million.

The Robotic Assisted Endovascular Systems Market involves the application of cutting-edge robotic technology in endovascular procedures, which are minimally invasive treatments conducted within blood vessels. These procedures primarily address a range of conditions, including cardiovascular diseases, peripheral artery diseases, aneurysms, and various vascular disorders.

Unlock Peak Performance - Get Your Sample Now:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17601

Several factors are driving the escalating demand for Robotic Assisted Endovascular Systems:

  1. Growing Disease Prevalence:The increasing incidence of cardiovascular diseases, peripheral artery diseases, and other vascular disorders is fueling the demand for advanced treatment options.
  2. Robotic Technology Advancements:Ongoing developments in robotic technology are equipping robotic-assisted endovascular systems with enhanced capabilities.
  3. Surgeon Adoption:An increasing number of surgeons are recognizing the potential benefits of integrating robotic systems into endovascular procedures, seeking state-of-the-art equipment and technology to enhance their efficiency and improve patient outcomes.

The Robotic Assisted Endovascular Systems Market’s growth signifies a promising shift towards advanced, minimally invasive treatments for vascular disorders, providing both patients and healthcare professionals with innovative and efficient solutions.

Key Players:

  • Siemens Healthcare
  • Stereotaxis, Inc

Key Developments in the Robotic Assisted Endovascular Systems Market:

  • Cathbot Robot Co., Ltd. (Shanghai Cathbot), developed a vascular interventional surgical robot. In August 2022, the company announced the conclusion of its clinical trial, making it the first robotic system to have finished a multicenter clinical trial in China, for vascular intervention. Further, the company is a collaboration between French company Robocath S.A.S (Robocath), R-ONETM and Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot)
  • In December 2018, 48 CorPath GRX Systems were deployed in hospitals around the United States, and four were installed abroad.

Robotic Assisted Endovascular Systems Market Segmentation:

By Product:

  • Systems
  • Software & Services

By Application:

  • Neurosurgery
  • Percutaneous coronary intervention
  • Peripheral vascular interventions
  • Electrophysiology procedures

By End User:

  • Hospital
  • Cath Lab

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East & Africa

 


aleena daniel

65 Blog posts

Comments